司库奇尤单抗治疗巨细胞动脉炎的真实世界有效性与安全性:意大利多中心队列研究
这项意大利14中心回顾性研究纳入36例接受司库奇尤单抗治疗的巨细胞动脉炎患者,随访至少6个月。结果显示12个月临床缓解率83.3%、无糖皮质激素缓解率40.0%,糖皮质激素日剂量中位数从基线8.7 mg降至12个月时0 mg,12个月药物留存率77.0%,不良事件发生率55.6%。
要点
- 司库奇尤单抗治疗GCA在真实世界中观察到较高的临床缓解率与逐步减少的激素用量。
- 12个月无激素缓解率达40.0%,激素日剂量中位数降至0 mg,42.9%患者停用激素。
- 不良事件发生率55.6%,感染发生率50.0%,需关注安全性。
核心结论
- 在包含复发和既往生物制剂暴露的GCA真实世界队列中,司库奇尤单抗与高缓解率、逐步减少激素剂量及增加无激素缓解相关。
- 尽管III期GCAptAIN试验未达到主要终点,这些发现提示白介素-17A抑制在GCA患者中值得进一步评估。
研究设计与样本
- 多中心回顾性研究,纳入意大利14个中心接受司库奇尤单抗治疗且随访至少6个月的GCA患者。
- 共纳入36例患者,女性占66.7%,司库奇尤单抗起始时中位年龄74岁(IQR 70-80)。
主要发现
- 88.9%(32/36)患者既往曾复发,72.2%(26/36)曾接受托珠单抗治疗。
- 第3、6、12个月临床缓解率分别为85.2%、80.6%、83.3%;完全缓解率分别为55.6%、52.8%、63.3%。
- 无激素缓解率在第3、6、12个月分别为14.8%、27.8%、40.0%(P = 0.012)。
- 糖皮质激素日剂量中位数从基线8.7 mg(IQR 4.0-21.2)降至12个月时0 mg(0-5.0)(P < 0.001);28例中12例(42.9%)停用激素。
- 12个月药物留存率为77.0%;55.6%(20/36)患者发生不良事件,50.0%(18/36)发生感染,共21次感染事件。
临床怎么用
- 对于复发或既往生物制剂暴露的GCA患者,司库奇尤单抗可作为真实世界中的治疗选择之一,有助于减少激素用量并提高无激素缓解。
- 治疗期间需监测感染等不良事件,本队列感染发生率达50.0%。
局限性
- 回顾性研究设计,样本量较小(36例),来自意大利多中心,结果外推需谨慎。
- 缺乏对照组,无法直接比较司库奇尤单抗与其他治疗的疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the real-world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). METHODS: This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow-up. Outcomes included clinical, complete, and glucocorticoid (GC)-free remission, GC dose reduction, drug retention rate, and adverse events. RESULTS: Thirty-six patients were included (66.7% women); median age at secukinumab initiation was 74 (interquartile range [IQR] 70-80) years. Overall, 32 of 36 patients (88.9%) had previously relapsed and 26 of 36 (72.2%) had received tocilizumab. Clinical remission was observed in 85.2%, 80.6%, and 83.3% at 3, 6, and 12 months, respectively. Complete remission occurred in 55.6%, 52.8%, and 63.3%, whereas GC-free remission increased progressively, reaching 14.8%, 27.8%, and 40.0% at 3, 6, and 12 months, respectively (P = 0.012). Median daily GC dose decreased from 8.7 (IQR 4.0-21.2) mg at baseline to 0 (0-5.0) mg at 12 months (P < 0.001); GCs were discontinued in 12 of 28 patients (42.9%). The 12-month retention rate was 77.0%. Adverse events occurred in 20 of 36 patients (55.6%); infections occurred in 18 of 36 patients (50.0%), accounting for 21 infectious episodes. CONCLUSION: In this multicenter, real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction, and increasing GC-free remission. Although the phase III GCAptAIN trial did not meet its primary endpoint, these findings suggest that interleukin-17A inhibition may warrant further evaluation in patients with GCA.
引用
- Iorio L, Davanzo F, Ricordi C, et al. Real-World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study. Arthritis Care Res (Hoboken). 2026. PMID: 42765445. doi:10.1002/acr.80167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。